Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
This is a dose escalation study. As subjects participating in the study tolerate a specific
dose level, the new subjects entering will be given a higher dose of the study drug.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Safety and Tolerability (Maximum Tolerated Dose)
After each cohort is enrolled .
Andrew Beelen, MD
United States: Institutional Review Board
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|
|Nevada Cancer Institute||Las Vegas, Nevada 89135|
|South Texas Accelerated Research Therapeutics||San Antonio, Texas 78229|